In Brief: QLT
QLT: Launch of Photofrin laser light-activated porfimer sodium cancer drug for advanced esophageal cancer by U.S. marketing partner Sanofi Winthrop scheduled for September pending FDA sign-off on promotional materials, QLT CEO Julia Levy tells an Aug. 13 session of the Medical Investments Northwest conference in Seattle. The product was approved in December ("The Pink Sheet" Jan. 15, T&G-4). Pivotal clinical trials with Photofrin will begin before year-end for treating Barrett's esophagus, a pre-cancerous condition. An SNDA will be filed for treatment of lung cancer "before the end of the year," Levy says...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth